|

Balstilimab Clinical Trials

17 actively recruiting trials across 10 locations

No change since May 2026

Also known as: AGEN 2034, AGEN-2034, AGEN2034, AGEN2034, anti-PD-1 antibody, BAL +3 more

Pipeline

Early 1: 1Phase 1: 3Phase 2: 8Phase 3: 2Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
  • Memorial Sloan Kettering Cancer Center2
  • Weill Medical College of Cornell University1
  • University of Southern California1
  • The Netherlands Cancer Institute1

Indications

Other5 trials

Baltimore, Maryland2 trials

Basking Ridge, New Jersey2 trials

Phase 2
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Duarte, California1 trial

Fullerton, California1 trial

Orange, California1 trial

Miami, Florida1 trial

Chicago, Illinois1 trial

Boston, Massachusetts1 trial

New York, New York1 trial

Phase 2

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.